SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is currently a focal point for intense community debate, with bulls citing potential regulatory catalysts and institutional accumulation, while bears argue the project faces obsolescence and persistent selling pressure. Traders remain heavily focused on its range-bound price action and the impact of broader market volatility, leading to a polarized environment between those holding for long-term recovery and those dismissing the asset as a speculative trap.

Maulcoin

Maulcoin is trending as the community rallies behind its aggressive social media presence and grassroots growth strategy, frequently pushing the project to the top of trending lists. Supporters are actively discussing plans for future airdrops and holding strategies while aiming to reach new market capitalization milestones without traditional chart listings.

Equinor ASA engages in the exploration, production, transport, refining, and marketing of petroleum and petroleum-derived products. It operates through the following segments: Exploration and Production Norway, Exploration and Production International, Exploration and Production USA, Marketing, Midstream, and Processing, Renewables, and Other. The Exploration and Production Norway segment includes the commercial development of oil and gas portfolios on the Norwegian continental shelf. The Exploration and Production International segment covers offshore and onshore activities in the USA, Mexico, and other operations worldwide. The Exploration and Production USA segment covers both onshore and offshore exploration, development, and Production of oil and gas in the USA. The Marketing, Midstream, and Processing segment markets and trades of crude oil and condensate, natural gas, NGL and refined products. The Renewables segment focuses on offshore wind, and integrated solutions for onshore renewables. The Other segment includes projects, drilling and procurement, the business area technology, digital and innovation, and corporate staffs and support functions. The company was founded on September 18, 1972 and is headquartered in Stavanger, Norway.

Equinor ASA - ADR

Equinor ASA

Equinor is attracting significant investor attention as global energy supply constraints and shifting geopolitical dynamics, particularly involving regional chokepoints and European natural gas demand, highlight its strategic importance. The community remains focused on the stock's fundamental value and dividend profile, debating its role as a stable energy play amidst ongoing market volatility and speculative long-term growth narratives.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending as investors weigh significant balance sheet improvements, including a recent debt-to-equity conversion by leadership, against concerns over potential future dilution to fund rapid manufacturing expansion. The community is actively debating the company's long-term potential as a critical supplier for defense and aerospace giants like Anduril and SpaceX, while closely monitoring the upcoming earnings report for clarity on revenue growth and profitability timelines.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is actively trending as the community leans into its legacy as a 15-year-old parody of Bitcoin, with investors debating its long-term potential compared to serious financial assets. Discussion is largely fueled by the project's historical roots and a growing community narrative that frames the meme as an inevitable fixture in the crypto space.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trading in a highly volatile landscape driven by a mix of political endorsements from the White House regarding its defense capabilities and ongoing skepticism from high-profile short sellers like Michael Burry. The community remains sharply divided, with bulls pointing to the company's entrenched role in government and defense infrastructure as a long-term moat, while bears argue that the valuation is disconnected from reality and faces potential competition from emerging AI models like Anthropic.

Dogelon Mars

Dogelon Mars continues to trend as the community engages in a heated debate over its long-term viability, with some investors holding out for potential breakthroughs linked to Elon Musk's ventures, while others express frustration over stagnant price action and lack of utility. Despite being viewed by many as an OG meme coin, sentiment remains deeply divided between 'diamond hands' hoping for a major turnaround and skeptics who characterize the project as a dormant pump-and-dump scheme.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is currently capturing investor interest as a resilient, high-yield defensive play amidst broader market volatility, with community sentiment bolstered by strategic fiber network expansions and upcoming earnings. Traders are closely monitoring the stock's support levels while discussing its role as a potential safe haven and long-term income vehicle.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

The community is currently divided over intense volatility in this meme coin, with supporters highlighting upcoming events and potential price rallies, while critics denounce the asset as a fraudulent pump-and-dump scheme tied to political figures. Sentiment remains highly polarized as discussions shift between speculative trading strategies and heated debates regarding the broader geopolitical implications and legitimacy of the project.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is experiencing significant community volatility, with holders fiercely debating whether current price action represents a strategic accumulation opportunity or a signal of deeper long-term decline. While some traders are actively buying the dip and anticipating future token burns, others are expressing frustration over stagnant performance and the silence of key project figures, highlighting a classic divide between dedicated memecoin believers and those who view the asset as a speculative pump-and-dump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Sellas will present new data on its CDK9 inhibitor SLS009 at the American Association for Cancer Research (AACR) meeting on April 21.</li><li>Preclinical findings showed SLS009 triggered leukemia cell death by increasing caspase-3 activity and reducing survival proteins such as MCL-1 and survivin.</li><li>Investor focus remains centered on the Phase 3 Regal study evaluating GPS as a maintenance therapy for AML patients in remission after relapse.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) rose 1% in premarket trading on Thursday as investors positioned ahead of an upcoming cancer conference presentation and a closely watched survival milestone in the company’s Phase 3 acute myeloid leukemia (AML) trial.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped 8% on Wednesday amid a volatile trading week.<h2 class="st-heading-2">AACR Preview: SLS009 Triggers Leukemia Cell Death Signals</h2>Sellas is preparing to present new preclinical data on its CDK9 inhibitor candidate SLS009 at the American Association for Cancer Research (AACR) annual meeting on April 21 in San Diego.Preclinical findings showed that SLS009 triggered leukemia cell death by increasing&nbsp;the&nbsp;activity of caspase-3, a key apoptosis protein, while lowering survival signals such as MCL-1 and survivin that help cancer cells persist. The drug also became more potent with repeated exposure, with early effects appearing within hours and strengthening over 24 hours.Notably, SLS009 remained active even in AML models carrying ASXL1 and TP53 mutations, which are associated with treatment resistance and poorer outcomes.<h2 class="st-heading-2">Investor Focus Remains On AML Survival Readout Timeline</h2>However, investor attention remains firmly focused on the company’s Phase 3 Regal trial evaluating GPS as a maintenance therapy for AML patients whose disease returned but later entered remission following additional treatment.GPS targets the Wilms Tumor-1 antigen, a protein commonly expressed across leukemia cells regardless of mutation status.The event-driven study will begin final analysis once 80 overall-survival events are recorded. Sellas previously said the contract research organization monitoring the trial had logged 72 events as of Dec. 26, bringing the study closer to the threshold required to initiate topline analysis.CEO Angelos Stergiou recently addressed speculation surrounding the timing of the readout on&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7444461539476197376/?originTrackingId=ExoqDp%2B3Mqnf9Ee3j3DVgA%3D%3D">LinkedIn</a>, noting that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than baseline expectations.Once the 80th event occurs, the company plans to proceed with database lock, statistical analysis, unblinding and disclosure of topline results.<h2 class="st-heading-2">How Does Retail Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS has slipped to ‘bearish’ from ‘extremely bullish’ levels a month ago amid a 23% dip in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_d73af252d9.webp" alt="sls ss.png" width="965" height="143"><figcaption>SLS sentiment and message volume as of April 9 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Princeb/message/649792805">said</a> SLS is “truly shaping up to be a once in a lifetime moonshot win.&nbsp; Don't miss your chance.”<stembedurl>https://stocktwits.com/Princeb/message/649792805</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Torben96/message/649792114">said</a>, “GPS is a safe harbour now, the IDMC meeting will reveal this. We should be worth 2B Dollar already.”<stembedurl>https://stocktwits.com/Torben96/message/649792114</stembedurl>SLS stock has surged 367% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bbby-ceo-pulls-opendoor-into-everything-home-turnaround-bet/cZJgy2ORIrB">Bed Bath &amp; Beyond CEO Pulls Opendoor Into ‘Everything-Home’ Platform Pivot</a>

SLS stock has surged 367% over the past year. (Photo credit: Getty Images)

SLS Stock Rises Premarket Ahead Of Cancer Summit This Month – Investors Eye Phase 3 AML Trial Milestone

SLS Stock - CEO Angelos Stergiou recently said that the slower accumulation of survival events can sometimes reflect longer patient survival.

Equity

CEO Angelos Stergiou recently said that the slower accumulation of survival events can sometimes reflect longer patient survival.

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 9.5%  - What's Next?

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.5% Higher - Here's What Happened...

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 7.7%  - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 7.7% - What's Next...

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

SELLAS Life Sciences Group, Inc. (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade

The consensus price target hints at a 63.6% upside potential for SELLAS Life Sciences Group, Inc. (SLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

<ul class="summary-bullets"><li>Investors weighed conflicting signals from Middle East diplomacy and braced for fresh labor market data.</li><li>AI trade tensions and regulatory risks kept Nvidia and chip-linked names under pressure.</li><li>U.S. President Trump will be holding a cabinet meeting at 10:00 am ET today.&nbsp;</li></ul>U.S. stock futures fell early Thursday as investors continued to parse the geopolitical developments in the Middle East. Amid conflicting reports, Iran is said to be reviewing a U.S. peace proposal delivered through Pakistan. Traders are also bracing for fresh macro signals with jobless claims data due later today. U.S. President Trump will be holding a cabinet meeting at 10:00 am ET today.&nbsp;As of 4:00 a.m. ET on Thursday, Dow, S&amp;P 500, and Nasdaq futures fell 0.4%, and Russell 2000 futures were down 0.6%.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has been languishing at ‘extremely bearish’ amid high trading volume.&nbsp;Trending Stocks To WatchNvidia (NVDA):&nbsp;The chipmaker remains in focus, with retail sentiment weakening to ‘bearish’ on Stocktwits. Calls are growing louder in Washington, with U.S. Senators Warren and Banks pushing to freeze export licenses over national security concerns.Meta Inc (META):&nbsp;It has lost another lawsuit alleging they made misleading claims about platform safety, adding to its growing list of legal headwinds.Destiny Tech100 (DXYZ):&nbsp;Garnering heavy retail interest as speculation around a potential SpaceX IPO grows this week.Micron (MU), Sandisk (SNDK):&nbsp;Memory stocks took a hit after reports that Google’s new AI model architecture could bring a significant impact on memory requirements.Super Micro (SMCI): The stock remained under pressure as shareholders filed a securities fraud lawsuit following recent allegations of chip smuggling.ImmunityBio (IBRX): The retail favorite biotech stock is back on traders’ radar after the company highlighted progress in its bladder cancer program and expanded trials targeting severe pneumonia and ARDS.&nbsp;Sellas Life Sciences (SLS): This pharma stock is gaining ground amid&nbsp;retail-trader speculation that Pfizer (PFE) may target the firm for an acquisition.urban-Gro (UGRO): The stock fell over 10% in early pre-market trading after surging over 400% in the previous session. Retail is bullish on the company’s new exposure to India’s fast-growing cricket economy following its merger with Flash Sports &amp; Media.Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Adma Biologics (ADMA), Upstart Holdings (UPST), Moonlake Immunotherapeutics (MLTX), NextDecade Corporation (NEXT), and Alphabet Inc (GOOGL).&nbsp;Other Catalysts To WatchOn the economic front, traders will be watching for the release of continuing jobless claims data at 8:30 am ET. Also keep an eye on commentary from a whole host of Fed Governors’ speeches through the day, including Fed Vice Chair for Supervision Michael Barr.On earnings radar, watch out for quarterly reports from Pulmatrix (PULM), BioRestorative Therapies Inc (BRTX), and POET Technologies Inc (POET), among others, today.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Fall Ahead Of Jobless Claims Data: Why NVDA, META, DXYZ, IBRX, SLS Are Keeping Traders Engaged Today

Data from Stocktwits shows that traders remain ‘extremely bearish’ on SPY and QQQ. 

<ul class="summary-bullets"><li>Investors compared Merck’s willingness to pay a 42% premium for mid-stage leukemia drug TERN-701 with Sellas’ AML pipeline opportunity.</li><li>Several retail investors pointed to Pfizer as a potential buyer, citing its ongoing expansion in hematologic cancers and need for post-COVID growth drivers.</li><li>Attention is focused on the Phase 3 Regal trial of GPS in AML relapse patients, which had recorded 72 of 80 required death events for final analysis as of late December.</li></ul>Shares of Sellas Life Sciences (SLS)&nbsp;jumped over 6% on Wednesday as Merck’s $6.7 billion acquisition of Terns Pharmaceuticals triggered renewed buzz on potential takeover targets across blood-cancer drug pipelines.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has risen 41% this quarter and has surged over 300% over the past year.<h2 class="st-heading-2">Merck’s Terns Deal Spurs Leukemia Interest</h2>Merck said it would acquire Terns for $53 per share in cash, representing a 42% premium to the 90-day average before the deal’s announcement.The acquisition adds TERN-701, an oral leukemia drug currently in early-to-mid-stage clinical testing, to Merck’s blood-cancer pipeline. The treatment is being studied for patients with chronic myeloid leukemia whose disease did not respond well to earlier therapies or who could not tolerate them.Now, retail investors are drawing comparisons between Merck’s willingness to pay billions for a mid-stage leukemia asset and the perceived commercial opportunity around Sellas’ pipeline.<h2 class="st-heading-2">Retail Traders Bet On Pfizer As Potential Buyer</h2>On Stocktwits, retail sentiment for SLS has remained in the ‘bearish’ zone over the past week amid an over 350% surge in message volume this quarter. The stock’s watcher base has jumped 20% over the past year.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_7ab67c1205.webp" alt="sls ss.png" width="968" height="144"><figcaption>SLS sentiment and message volume as of March 26 | Source: Stocktwits</figcaption></figure>Sentiment over the past day has increasingly centered on Pfizer as a potential acquirer following the Merck-Terns deal. One trader&nbsp;<a href="https://stocktwits.com/MarcoFla99/message/648580457">said</a>, “My $$ is on PFE to acquire SLS.”The investor pointed to Pfizer’s ongoing clinical work on Mylotarg in CD33-positive acute myeloid leukemia (AML), noting that the company is conducting a prospective surveillance study to evaluate the drug’s safety and effectiveness in newly diagnosed patients as part of its push into hematologic cancers.Another trader argued Pfizer may be seeking a major oncology win following the pandemic-era revenue decline,&nbsp;<a href="https://stocktwits.com/OnTheBalance/message/648587881">saying</a>, “They need a clear win to bury the COVID era and leave it behind… What is better than a cancer moonshot?”Another investor&nbsp;<a href="https://stocktwits.com/OnTheBalance/message/648587881">highlighted</a> motivations behind possible acquisitions, saying “PFE stock and shareholders [are] looking desperately for a powerful boost.”<h2 class="st-heading-2">Retail Traders Run Buyout Valuation Scenarios</h2>One retail investor&nbsp;<a href="https://stocktwits.com/Duncan74/message/648577739">estimated</a> that applying a typical 5x-8x peak-sales multiple to projected revenue of about $5.5 billion for Sellas’ lead AML candidate, Galinpepimut-S (GPS), and $1.2 billion for its CDK9 inhibitor, SLS-009, could imply a valuation range of roughly $33.5 billion to $53.6 billion.Another trader compared the Merck-Terns transaction directly with Sellas’ opportunity: “If TERN was acquired by MRK for 8.8b. and our product has market size smaller than TERN. our upside should be 4x-6x?”A separate user discussed potential acquisition structure scenarios,&nbsp;<a href="https://stocktwits.com/JdlawVT40/message/648584776">saying</a>, “Wouldn’t a PFE stock purchase be sweet. All long term holding period and a 6.30 dividend. Four to one share SLS.”Another trader&nbsp;<a href="https://stocktwits.com/Johnmtnb2018/message/648533707">suggested</a> the setup for a deal may already be in place: “The table is now fully set for interested pharma’s to finish a deal!” One investor also&nbsp;<a href="https://stocktwits.com/Laacy/message/648584092">outlined</a> a portfolio strategy for a possible acquisition, saying, “If PFE offers id sell my options. Keep 33% as pfizer shares if share based and sell the rest.”<h2 class="st-heading-2">GPS Catalyst Aligns With Pfizer Moves</h2>Investor attention remains focused on Sellas’ Phase 3 Regal trial evaluating GPS in AML patients whose cancer returned and then went back into remission after additional treatment. The study is designed to reach its final analysis after 80 patient death events, with 72 recorded as of Dec. 26 while the trial remained fully blinded, placing the program closer to a potential results-driven catalyst.Merck’s move to buy TERN-701 underscores continued demand for blood-cancer assets, while Pfizer has been stepping up investment in oncology as it looks to rebuild growth after the sharp decline in COVID vaccine revenues and increasing competition across several aging products.&nbsp;The company has expanded its cancer pipeline through initiatives including its $1.25 billion upfront licensing deal with 3SBio, ongoing development of Mylotarg in AML and progress with Tukysa in breast cancer.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-vs-tern-which-stock-has-more-upside-ahead-of-keytruda-patent-cliff/cZ3YKepRI16">SLS Vs. TERN: Which Pharma Stock Has More Upside As Merck Eyes $6B Cancer Bet Ahead Of Keytruda Patent Cliff</a>

SLS stock has risen 41% this quarter and has surged over 300% over the past year. (Photo credit: Getty Images)

SLS Stock Jumps After Merck's Tern Deal Sparks Buyout Buzz In Blood-Cancer Space: Retail Bets On This Big Pharma Suitor

Merck’s acquisition of Terns underscores strong big-pharma demand for blood-cancer assets, as Pfizer also expands its oncology pipeline.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

SLS Vs. TERN: Which Pharma Stock Has More Upside As Merck Eyes $6B Cancer Bet Ahead Of Keytruda Patent Cliff

SLS vs TERN Stock - Analyst estimates suggest SLS may offer 73% upside, versus 16% for TERN, despite takeover momentum supporting TERN’s shares.

Analyst estimates suggest SLS may offer 73% upside, versus 16% for TERN, despite takeover momentum supporting TERN’s shares.

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 8.5%  - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.5% - Time to Sell...

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 12.9% - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 12.9% - Here's What Happened...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Warranted - fundamentals justify the decline

Overdone - the market is overreacting

Too early to tell

Is the selloff in software stocks warranted or overdone?

Stocktwits

Stocktwits Polls

Investors are closely monitoring the potential for a mid-trial clinical halt by the IDMC based on groundbreaking efficacy data.

A massive accumulation of over 53 million shorted shares is creating high expectations for a violent repricing event.

The upcoming oncology conference is expected to be a major catalyst for company awareness and potential strategic updates.

Discussions are heating up around the potential curative capabilities of proprietary peptide technologies for various cancer indications.

Current Price	$4.76
Prev Close	$5.05
Open	$5.03
Dividend Yield	0.00%
50-Day Moving Average	$4.59
Beta	0.82
Avg. Volume	8.3M
PE Ratio	-19.36

52-Week High	$6.14
52-Week Low	$1.11
Market Capitalization	$854.81M
EPS (Annual)	-$0.2463
Price to Book	10.28
Revenue Per Employee	$0.00

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc